Aiconno Pharmaceutical

Aiconno Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of small molecule drugs for metabolic and inflammatory diseases. The company's lead program, ACN-001, is a selective thyroid hormone receptor beta (THR-beta) agonist designed to treat non-alcoholic steatohepatitis (NASH) and related metabolic disorders. Aiconno aims to address significant unmet clinical needs through its internal drug discovery platform and strategic focus on validated biological pathways. The firm has secured significant venture capital funding from leading investors such as Lilly Asia Ventures and Qiming Venture Partners to advance its clinical pipeline. Its research facilities are located in the Suzhou Industrial Park, a major hub for biotechnology innovation in China.